iShares Bitcoin Trust vs ImmunityBio Inc. Common Stock — how do they compare? iShares Bitcoin Trust trades at $46.73 (market cap $68.92B), while ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.33B). The key difference: iShares Bitcoin Trust is far larger — about 6.7× ImmunityBio Inc. Common Stock's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and ImmunityBio Inc. Common Stock for 0 Days on average.
| IBIT | IBRX | |
|---|---|---|
Market Cap | $68.92B | $10.33B |
Volume | 46,059,179 | 11,745,198 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $11.55 |
52-Week Low | $33.29 | $1.98 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $10.79B |
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.21, down 2.64% on the day, with technical indicators showing a bullish overall signal driven by moving averages. The stock faces immediate support at $46 and resistance at $48. Recent news highlights strong institutional interest with BlackRock's IBIT recording $196 million in daily inflows on October 1, 2026, signaling renewed investor confidence in Bitcoin-focused investment products.
The outlook remains cautiously optimistic given institutional inflows and technical strength, though the absence of traditional financial metrics like P/E and P/S limits fundamental analysis. Key risks include market volatility and regulatory uncertainty, while analyst sentiment appears mixed with technical indicators favoring bullish momentum near-term.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →